ERBB2: erb-b2 receptor tyrosine kinase 2
1 protein, 781 patents, 50 drugs, 2,589 trials, 24,100 NIH grants and 150,300 papers.
Gene 7
Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.
Proteins 1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in | Source |
|---|---|---|---|---|---|
| P04626 | Receptor tyrosine-protein kinase erbB-2 | 1,255 | 63 | Ensembl, GeneID, HGNC | UniProt |
Patents 781
Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026220001 A1 | 2026-10-22 | 100 | P04626 | Espacenet |
| WO 2026215173 A1 | 2026-10-15 | 74 | P04626 | Espacenet |
| WO 2026193167 A1 | 2026-09-17 | 1 | P04626 | Espacenet |
| WO 2026167227 A1 | 2026-08-13 | 4 | P04626 | Espacenet |
| EP 4782064 A2 | 2026-07-29 | 2 | P04626 | Espacenet |
| JP 2026120541 A | 2026-07-22 | 37 | P04626 | Espacenet |
| JP 2026117046 A | 2026-07-14 | 16 | P04626 | Espacenet |
| WO 2026121966 A2 | 2026-06-11 | 3 | P04626 | Espacenet |
| US 12649001 B2 | 2026-06-09 | 41 | P04626 | Espacenet |
| JP 2026086770 A | 2026-05-26 | 16 | P04626 | Espacenet |
Drugs 50
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AC-480 | CHEMBL1645462 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| AEE-788 | CHEMBL587723 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| AFATINIB | CHEMBL1173655 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| AFATINIB DIMALEATE | CHEMBL2105712 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| ALLITINIB | CHEMBL1947204 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Receptor protein-tyrosine kinase erbB-2 binding agent | BINDING AGENT | ChEMBL |
| AV-412 | CHEMBL6067986 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| AV-412 FREE BASE | CHEMBL2138625 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| BMS-690514 | CHEMBL3545396 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
| CANERTINIB | CHEMBL31965 | Receptor protein-tyrosine kinase erbB-2 inhibitor | INHIBITOR | ChEMBL |
Trials 2589
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07597993 | TRASTUZUMAB DERUXTECAN | ClinicalTrials.gov | ||
| NCT07597629 | KN-026 | PHASE2 | ClinicalTrials.gov | |
| NCT07589972 | TRASTUZUMAB | ClinicalTrials.gov | ||
| NCT07589972 | PERTUZUMAB | ClinicalTrials.gov | ||
| NCT07584733 | DISITAMAB VEDOTIN | PHASE2 | ClinicalTrials.gov | |
| NCT07582887 | TRASTUZUMAB DERUXTECAN | ClinicalTrials.gov | ||
| NCT07581795 | TRASTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07581795 | PERTUZUMAB | PHASE2 | ClinicalTrials.gov | |
| NCT07581574 | TRASTUZUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT07578116 | TRASTUZUMAB | PHASE3 | ClinicalTrials.gov |
NIH grants 24100
NIH projects whose papers are about the gene, through NIH's grant-paper links.
| Project | Title | Its papers about the gene | Newest fiscal year | Source |
|---|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 1,717 | 2,025 | NIH's project files |
| P30CA016672 | Cancer Center Support Grant | 1,591 | 2,025 | NIH's project files |
| P50CA058223 | SPORE in Breast Cancer | 338 | 2,025 | NIH's project files |
| P30CA006973 | Regional Oncology Research Center | 284 | 2,025 | NIH's project files |
| P30CA068485 | Cancer Center Support Grant | 257 | 2,025 | NIH's project files |
| P30CA016086 | Cancer Center Support Grant | 231 | 2,025 | NIH's project files |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 230 | 2,025 | NIH's project files |
| P50CA116201 | Mayo Clinic Breast Cancer SPORE | 218 | 2,025 | NIH's project files |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 202 | 2,025 | NIH's project files |
| P30CA016058 | Cancer Center Support Grant | 196 | 2,025 | NIH's project files |
Papers 150300
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| PMID | Found by | Source |
|---|---|---|
| 42827257 | PubTator, text mining | PubMed |
| 42826678 | PubTator, text mining | PubMed |
| 42826440 | PubTator, text mining | PubMed |
| 42825982 | PubTator, text mining | PubMed |
| 42825938 | PubTator, text mining | PubMed |
| 42825881 | PubTator, text mining | PubMed |
| 42825812 | PubTator, text mining | PubMed |
| 42824934 | PubTator, text mining | PubMed |
| 42824931 | PubTator, text mining | PubMed |
| 42824666 | PubTator, text mining | PubMed |
Release gene-search-2026-11-11-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
HGNC: CC0: https://www.genenames.org/about/license/
NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH's project files and grant-paper links: Public domain (NIH RePORTER)
Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubTator 3: Public domain
UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license